Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients

Shots:

• The data from P-III (DESTINY-Gastric04) study showed statistically significant and clinically meaningful improvement in OS vs ramucirumab & paclitaxel in 2L HER2+ (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or GEJ adenocarcinoma pts.
• The safety profile observed in DESTINY-Gastric04 aligns with Enhertu’s established safety record. The company expects to present data from the study at an upcoming medical meeting and share it with global regulatory authorities
• Daiichi Sankyo discovered Enhertu, which is being jointly developed and commercialized by Daiichi Sankyo & AstraZeneca; based on various studies, Enhertu is approved in 65+ countries

Ref: Daiichi Sankyo | Image: Daiichi Sankyo

Related News:- AstraZeneca and Daiichi Sankyo Receive CHMP’s Positive Opinion for Datroway to Treat HR+/HER2- Breast Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com